Compare IGC & MODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IGC | MODD |
|---|---|---|
| Founded | 2005 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.2M | 33.0M |
| IPO Year | N/A | N/A |
| Metric | IGC | MODD |
|---|---|---|
| Price | $0.30 | $0.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.13 | N/A |
| AVG Volume (30 Days) | ★ 936.3K | 599.5K |
| Earning Date | 02-17-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,106,000.00 | N/A |
| Revenue This Year | $3.54 | N/A |
| Revenue Next Year | $15.12 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.25 | $0.28 |
| 52 Week High | $0.50 | $1.49 |
| Indicator | IGC | MODD |
|---|---|---|
| Relative Strength Index (RSI) | 37.86 | 48.50 |
| Support Level | $0.29 | $0.32 |
| Resistance Level | $0.31 | $0.42 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 18.27 | 57.15 |
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.